Search

everythinglearnresearchcommunity

for

Search:↓

KX-826 is available on Amazon but not shipped to the Netherlands. The user seeks advice on obtaining it in Europe.

HairClone received grant money to start work after crowdfunding failed. They aim to offer treatments in early 2021, pending UK FDA licensing.

The conversation discusses future hair loss treatments, with mentions of dutasteride potentially gaining FDA approval and increased popularity. Skepticism remains about significant advancements due to limited funding and reliance on cosmetic companies.

Kintor Pharma has started a Phase II trial in China for GT20029, a potential new treatment for hair loss. Participants are discussing the significance, potential release dates, and comparing it to other treatments and technologies like stem cell hair transplants and SAMIRNA.

A clinical trial for Verteporfin as a hair loss treatment, and the potential for greater progress in treatments for hair loss in the future. Common treatments such as Minoxidil, Finasteride and RU58841 were discussed.

Lower levels of Ferritin and iron are linked to male pattern baldness. Checking these levels could provide clinical benefits.

A user discovered CosmeRNA, a new hair loss treatment with clinical research backing, set to release soon. The conversation revolves around its potential effectiveness, cost, and how it compares to existing treatments like Minoxidil and Finasteride, with some users expressing hope for a side-effect-free option.

Exploring the potential of exosomes to treat hair loss and discussing the effectiveness of treatments such as Minoxidil, Finasteride and RU58841.

KX-826 initially improves hair growth but declines after 24 weeks, with mild itching as a side effect. Combining it with minoxidil and finasteride may improve results, but long-term effectiveness is uncertain.

The conversation discusses the failure of Phase 3 trials for the hair loss treatment KX-826, with no significant difference found between the drug and placebo. Some users express disappointment and skepticism, while others discuss alternative treatments like Minoxidil, finasteride, and RU58841.

The conversation is about the delay in receiving updates on the HMI-115 phase 1 trial for hair loss. No specific treatments are mentioned in the conversation.

A user is testing clascoterone (Winlevi) on their scalp for hair loss and has noticed a reduction in scalp sebum after one month. They are also using other unspecified treatments and plan to provide an update after the second month.

A 23 year old user's 6 month progress with treatments of 1mg finasteride daily, 5% minoxidil daily, keto shampoo and microneedling once weekly for hair loss. The conversation was encouraging with replies showing admiration for the user's rapid regrowth.

A user's journey to try and stop their hair loss, including the use of oral finasteride, topical minoxidil, ketoconazole shampoo, Cynatine Keratin supplements, and The Ordinary's Multi-Peptide Serum for Hair Density; and advice from other users regarding trying dutasteride, oral minoxidil, and lifestyle changes.

The conversation discusses hair loss treatments using oral minoxidil, oral dutasteride, and mesotherapy dutasteride, showing impressive 6-month results. The user wishes these treatments were available in the U.S.

The conversation discusses an 8.5-month progress of using Minoxidil, Finasteride, and RU58841 for hair loss. People are complimenting the user on the significant improvement in hair thickness.

A male with early-stage hair loss experienced severe side effects, including sexual dysfunction from finasteride and increased heart rate and fatigue from high-dose minoxidil, leading to discontinuation of both treatments. He is now relying on DHT-blocking shampoos and awaiting new treatments.

A 37-year-old male resolved scalp folliculitis by adopting a low-histamine diet and taking Vitamin A, Zinc, and Fish Oil, leading to better skin health and thicker hair. He warns about the potential toxicity of excessive Vitamin A intake.

A 17-year-old user reports significant hair regrowth using 1mg finasteride daily and 5% minoxidil once daily. Other users discuss the effectiveness and age considerations of finasteride.

. This conversation discussed the efficacy of Minoxidil and Finasteride as treatments for hair loss, with a focus on the potential side effects of taking Oral Minoxidil. Some users shared their experiences with both treatments and there was debate over whether they were safe or not.

A user is joining a clinical trial for Clascoterone, a drug approved for acne but being tested for hair loss. They previously tried finasteride with limited success and plan to share updates on their experience with the new treatment.

SCUBE3 clinical trials for hair loss treatment to start this year. Treatment may involve regular, painless scalp injections to maintain hair growth.

The conversation discusses Breezula, a hair loss treatment, and its Phase 3 clinical trial recruitment at 50 locations. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.

Pyrilutamide did not show effectiveness in regrowing hair compared to a placebo, but it may still help maintain existing hair by preventing DHT from causing follicle miniaturization. Some users believe it could be beneficial when used with other treatments like minoxidil, finasteride, and dutasteride.

A Phase II clinical trial for TDM-105795 has started recruiting in the US, and it might be a promising treatment for hair loss. Many hair loss drugs, including this one, originate from China.

12 companies having drugs or therapies in clinical trials during 2023, with various molecules and phases of trial; the probability that some may fail; and progress being made in the field.

A monoclonal antibody clinical trial for potential hair loss treatments in Victoria, Australia and the discussion of their efficacy. People shared information about similar drugs already on the market, speculated about potential side effects, and discussed how to spread the word about the trial.

The conversation discusses the safety, tolerability, and efficacy of oral Setipiprant tablets for treating androgenetic alopecia compared to finasteride. It mentions the high cost of Setipiprant on the black market and the trial's end date in September 2017.

David Barreto shared that a London-based research group is conducting a 12-month trial for a new nutraceutical treatment for pattern hair loss, designed with Dr. Carlos Puig. The trial aims to provide robust data, with results expected in 1-2 years, potentially representing a significant advancement since finasteride’s introduction in 1997.